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The effect of enhancing insulin’s actions in endothelial
cells (ECs) to improve angiogenesis and wound healing
was studied in obesity and diabetes. Insulin receptor
substrate 1 (IRS1) was overexpressed in ECs using the
VE-cadherin promoter to create ECIRS1 TG mice, which
elevated pAkt activation and expressions of vascular
endothelial growth factor (VEGF), Flk1, and VE-cadherin
in ECs and granulation tissues (GTs) of full-thickness
wounds. Open wound and epithelialization rates and an-
giogenesis signiﬁcantly improved in normal mice and high
fat (HF) diet–induced diabetic mice with hyperinsulinemia
in ECIRS1 TG versus wild type (WT), but not in insulin-
deﬁcient diabetic mice. Increased angioblasts and EC
numbers in GT of ECIRS1 mice were due to proliferation
in situ rather than uptake. GT in HF-fed diabetic mice
exhibited parallel decreases in insulin and VEGF-induced
pAkt and EC numbers by >50% without changes in angio-
blasts versus WT mice, which were improved in ECIRS1
TG mice on normal chow or HF diet. Thus, HF-induced
diabetes impaired angiogenesis by inhibiting insulin sig-
naling in GT to decrease the differentiation of angioblasts
to EC, which was normalized by enhancing insulin’s ac-
tion targeted to EC, a potential target to improve wound
healing in diabetes and obesity.
Every step of the complex process of wound healing has
been reported to be defective, including impairments of
neutrophil activation and responses, ﬁbroblast migration
and proliferation, and angiogenesis (1–5). Poor glycemic
control, neuropathy, presence of micro- and macrovascular
complications, and insulin resistance are associated with
impaired wound healing (6). Most strategies devised to
improve chronic wound healing in patients with diabetes
have not exhibited clear efﬁcacy, possibly due to a lack of
full understanding of the mechanisms induced by diabetes
to impair the wound healing process (5–8).
One major factor that contributes to impaired wound
healing in diabetic and insulin-resistant states is reduced
angiogenesis in the granulation tissue (GT), which could
be the result of decreased vascular endothelial growth
factor (VEGF) expression or its actions in response to
hypoxia (4,9,10). Multiple metabolic abnormalities can
affect VEGF expression and actions, including hyperglycemia-
related oxidative stress, glycation products, and activation
of protein kinase C (PKC) (10–13). Systemic insulin resis-
tance could also affect angiogenesis because insulin’s signal-
ing can regulate VEGF expression, which has been reported
to be inhibited in diabetes (14,15). Thus, we postulate that
insulin resistance may exist in the GT to impair angiogen-
esis, by inhibiting insulin signaling to enhance VEGF ex-
pression and actions.
Insulin receptors are present in many cells of the
GT, including keratinocytes, ﬁbroblasts, endothelial cells
(ECs), and inﬂammatory cells (16–21). Mice with deletion
of insulin receptors in the ﬁbroblasts and myocardium
exhibited decreases in VEGF expression and capillary den-
sity in response to hypoxia (14). Insulin can induce VEGF
expression mostly through the IRS1/PI3K/Akt pathway,
which is selectively inhibited in insulin resistance and di-
abetes (14,15,22–24). Activation of pAkt affected VEGF
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secretion in keratinocytes and angiogenesis in cutaneous
wound healing (25–27). The ﬁnding that insulin resis-
tance may impair wound healing also suggests that differ-
ential pathogenic mechanisms may exist for defective
wound healing associated with diabetes due to insulin
deﬁciency or resistance with hyperinsulinemia. This study
investigated the regulation of the insulin signaling path-
way in GT and on the differentiation of angioblasts to ECs
in the GT using rodent diabetic models of insulin deﬁ-
ciency or hyperinsulinemia and insulin resistance.
RESEARCH DESIGN AND METHODS
Wild-type (WT) C57/BL6J mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). Recombinant
human VEGF (R&D Systems, Minneapolis, MN) and an-
tibodies to pAkt, Akt, pErk, Erk1/2, ﬁbronectin, IRS1 (Cell
Signaling, Danvers, MA), VCAM1 (Millipore, Billerica,
MA), Flk1, eNOS (BD Biosciences, San Jose, CA), and
b-actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
were obtained commercially.
Animals
All protocols for animal use and euthanasia were ap-
proved by the Animal Care Committee of the Joslin
Diabetes Center and are in accordance with National
Institutes of Health (NIH) guidelines. Mice with endothelial-
speciﬁc overexpression of IRS1 (ECIRS1 TG) with VE-cadherin
promoter were described previously (28) (Supplementary
Fig. 1A). The following primers were used for IRS1 geno-
typing: 59-ATCTGCAGGCAGCTCACAAAG-39 and 59-CGAA
GAAGCGTTTGTGCATGC-39. Two mice models of diabetes
were used. 1) For hyperinsulinemia with insulin resistance
and hyperglycemia, male mice at age 4 weeks were fed with
normal chow (NC) (3.3% kcal fat) or high fat (HF) (60%
kcal fat) for 10 weeks (28). Insulin-deﬁcient diabetic mice
were produced by ﬁve consecutive days of intraperitoneal
injection of 50 mg streptozotocin (STZ)/kg body weight
(Sigma-Aldrich, St. Louis, MO), and fasting blood glucose
concentrations .400 mg/dL were documented. Insulin
treatment was performed using insulin pellet (LinShin Can-
ada, Inc., Scarborough, Ontario, Canada) placed subcutane-
ously and with a release rate of 0.1 unit/day/insulin pellet,
which was adjusted to maintain plasma glucose at 150 mg/dL
range (at steady state) in STZ-induced diabetic mice for
2 weeks. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed as previously described (29).
Wound Healing Model
Mouse dorsal hair was depilated on the day before surgery
(Nair; Church & Dwight Co., Inc., Ewing, NJ), and mice
were anesthetized by isoﬂurane inhalation (isoﬂurane,
USP; NOVAPLUS, Lake Forest, IL). Their dorsum was dis-
infected with 70% alcohol and marked with standard
square template (1.0 cm2). Skin plus panniculus carnosus
was excised to create a full-thickness dorsal excisional
wound, which was covered with transparent, semiocclusive
adhesive polyurethane dressings (Tegaderm; 3M, St. Paul,
MN) and changed two times per week (30–32).
Tissue Morphometric Analysis
Digital macroscopic images of the wound were analyzed
using NIH ImageJ software version 1.40 (Bethesda, MD).
Standardized photographs were taken on the day of surgery
and on the 3rd, 7th, 10th, and 14th days for 14 days from
a standard height. Re-epithelialization and open wound
surface were measured as a percentage of the initial wound
area as published (30–32).
Wound kinetics were quantiﬁed as follows: open
wound rate (OWR) = open wound/initial area of wound
size, contraction rate (CR) = contraction/initial area of
wound size, and epithelialization rate (ER) = epitheliali-
zation/initial area of wound size 2 contraction (30,31).
On days 3, 7, and 10 postsurgery, wounds from seven to
eight animals in each group were harvested as previously
described (32).
For signaling studies, insulin (1 unit/kg body weight)
was administrated intravenously and GTs were col-
lected 10 min afterward. For histological studies, ex-
cised tissues were ﬁxed in 4% formalin at 4°C. Panoramic
cross-sectional digital images of each wound were exam-
ined using an FSX100 microscope (Olympus, Center Val-
ley, CA).
Immunoﬂuorescence Studies
Immunohistochemistry studies were performed using
parafﬁn sections and incubated with 0.5% BSA and rabbit
mAbs to CD31 (Dianova GmbH, Hamburg, CA) as pri-
mary antibody to identify EC, followed by Alexa Flour 488–
conjugated secondary antibodies (Invitrogen, Gland Island,
NY). Nuclei were counterstained with DAPI (Invitrogen).
Quantitative ﬂuorescent analyses were performed using an
FSX100 microscope and Adobe Photoshop CS Software
(San Jose, CA).
Immunoblot and Immunoprecipitation Studies
GT, frozen in dry ice, was homogenized in ice-cold tissue
lysis buffer, as previously described (33). Protein concen-
tration was determined by Bradford assay and processed
as previously described (33).
Real-Time PCR
Real-time PCR procedures were used to assess mRNA
levels (Applied Biosystems, Grand Island, NY) and nor-
malized to 36B4 or 18S rRNA. PCR primers used in the
study are listed in Supplementary Table 1.
Culture of ECs
Lung tissues from c57/BL6J mice were used to obtain
primary ECs and used between passages three and ﬁve
(33,34). ECs were incubated for 16 h in DMEM containing
0.1% BSA and stimulated with 100 nmol/L insulin for
24 h. Expression of VEGF165 in media was measured
by an ELISA kit (R&D Systems).
Bone Marrow Cell Transplantation
Bone marrow (BM) cells from green ﬂuorescent protein
(GFP)–expressing mice (The Jackson Laboratory) were har-
vested from tibias and femurs by ﬂushing with Dulbecco’s
PBS + 5% FBS and were resuspended and ﬁltered through a
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70-mm cell strainer (35). Erythrocytes were depleted using
ACK lysis buffer (Lonza, Basel, Switzerland). BM cells were
stained with lineage marker mix (Lin: anti-CD3e [17-A2],
anti-CD4 [L3T4], anti-CD8 [53-6.72], anti-B220 [RA3-
6B2], anti–TER-119, anti–Gr-1 [RB6-8C5], and anti–Mac-1
[M1/70]; eBioscience, San Diego, CA). Flow cytometry–
sorted lineage-negative cells were transplanted intrave-
nously (2 3 106 cells/mouse) into congenic recipient
mice and analyzed 7 days after transplantation (36).
Evaluating Proliferation In Vivo
At 4 and 6 days postwounding, BrdU (100 mL) was injected
intraperitoneally and BrdU in angioblasts or ECs from blood
and GT was detected by ﬂow cytometry after 7 days (FITC
BrdU Flow Kits; BD Pharmingen, San Jose, CA) (37).
Flow Cytometry of Cells in GT
Dissected GTs were incubated with collagenase I and II,
DNase, and hyaluronidase in Hepes buffer for 30 min at 37°C
Figure 1—Characterization of insulin signaling and VEGF expression in lung ECs and GT of WT and ECIRS1 TG mice. A: IRS1 protein
expression in lung ECs. B: VEGF mRNA expressions in cultured ECs from WT and ECIRS1 TG mice with insulin stimulation (100 nmol/L) at
1, 3, and 8 h. C: Secreted VEGF protein levels in the media of cultured ECs from WT and ECIRS1 TG mice with insulin stimulation
(100 nmol/L) at 0, 12, and 24 h. D: IRS1 protein expressions in GT in WT and ECIRS1 TG mice at 7 days postsurgery. E: Total Akt
(tAkt) and pAkt expressions at 7 days in GT. F: eNOS expression in GT. G: Total Erk (tErk) and pErk expressions in GT. *P < 0.05; **P <
0.01. n = 4 in A and n = 5 in B–G.
2762 IRS1 Overexpression and Wound Healing Diabetes Volume 65, September 2016
and then ﬁltered through a 70-mm cell strainer with eryth-
rocytes depleted by ACK lysis buffer. Cells were incubated
with insulin (100 nmol/L) and anti-CD16/32 (BioLegend,
San Diego, CA), ﬁxed in 2% formaldehyde, and permeabi-
lized using the Perm/Wash Buffer (BD Biosciences, San
Diego, CA) followed by incubation with monoclonal anti-
bodies: anti-CD45 for leukocyte, anti-CD31 for EC, or anti-
Flk1, marker for angioblast and PI for viability. Rabbit
anti-Akt and rabbit anti–phospho-Akt (Ser473) were used
to detect Akt activation, which were followed with Alexa
Fluor 647 goat anti-rabbit IgG. All populations were rou-
tinely k-gated to verify purity and gating. One million cells
from BM or 200,000 cells from GT were analyzed using
FlowJo software version 10.0 (Tree Star, Inc., Ashland, OR).
Statistical Analysis
Values are expressed as mean and SEM. Student t tests
were performed for comparison of two groups. One-way
ANOVA, followed with Tukey-Kramer, was performed for
comparisons of multiple groups using SPSS 22.0 (SPSS,
Inc., Chicago, IL). A value of P , 0.05 was considered
signiﬁcant.
RESULTS
Characterization of ECIRS1 Transgenic Mice and
Insulin Signaling in GT
To enhance insulin’s actions, IRS1 was overexpressed in
the EC using VE-cadherin promoter to produce ECIRS1
TG mice, which elevated IRS1 expression in the EC by
Figure 2—Comparison of wound healing among WT, ECIRS1 TG, STZWT, and STZECIRS1 TG mice. A: Photographs of wound at 0, 3, 7,
10, and 14 days in WT and ECIRS1 TG mice. B: STZWT and STZECIRS1 mice. Black bars, 1 cm. C: OWR. D: CR. E: ER (n = 5). **P < 0.01.
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170% and in the lung and retina, but not in peripheral blood
mononuclear cells (Fig. 1A and Supplementary Fig. 1B and
C). Metabolically, WT and ECIRS1 TG mice did not differ by
glucose tolerance as measured by IPGTT and fasting plasma
insulin levels (Supplementary Fig. 1D and E).
Insulin increased VEGFB mRNA expression by 240% at
1 and 3 h and protein levels in the media by 200% after
24 h in ECs from ECIRS1 TG mice versus WT mice (Fig.
1B and C). IRS1 protein expression was increased in GT
from ECIRS1 TG mice by 72% as compared with WT mice
(P , 0.01) (Fig. 1D). Further, Akt phosphorylation (pAkt)
in the GT of ECIRS1 TG mice was signiﬁcantly increased
at basal (261%, P, 0.05) and after the addition of insulin
(480%, P , 0.01) compared with WT (Fig. 1E), without a
difference in insulin’s activation of Erk (pErk) (Fig. 1G).
Expressions of eNOS, a marker of capillary density, in the
GT also signiﬁcantly increased by 133%, comparing ECIRS1
TG to WT mice. (Fig. 1F).
Insulin’s Actions on Wound Healing in Control and
STZ-Induced Diabetic Mice
The effect of increasing IRS1 expression and insulin’s
actions in EC on wound healing was evaluated by com-
paring OWR, CR, and ER in WT and ECRIS1 TG mice (Fig.
2A and B). The results indicated that OWR decreased
more rapidly in ECRS1 TG mice versus WT mice with
improvements at 3 and 7 days (P , 0.01) (Fig. 2C). CR
was signiﬁcantly improved on day 14 and ER was in-
creased in ECRIS1 TG mice by 96 and 48% on 3 and
7 days, respectively (Fig. 2D and E). VEGF mRNA and
FLK1 protein expressions in the GT were also increased
signiﬁcantly on day 7, and VE-cadherin expression was
increased on day 10 (Fig. 3E). No changes in ﬁbronectin
were observed comparing ECIRS1 TG to WT mice (Fig. 3C).
STZ-induced diabetic ECIRS1 TG and WT mice had
comparable weights and fasting blood glucose of .500
mg/dL during the study (Supplementary Fig. 2A and B),
Figure 3—Analysis of genes for vessels in GT in VEGF mRNA expressions (A), VE-cadherin mRNA expressions (B), Flk1 expression (C), and
ﬁbronectin mRNA (D) at 3, 7, and 10 days postsurgery in the GT from WT and ECIRS1 TG mice (n = 7 at each time point). E: VEGF mRNA
levels in the GTs from WT, ECIRS1, WTHF, and ECIRS1HF mice at 7 days postsurgery. *P < 0.05; **P < 0.01. n = 7.
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with comparable plasma insulin levels of ,0.2 ng/mL,
which were four times lower than nondiabetic mice (Sup-
plementary Fig. 2C). STZ diabetes delayed OWR, CR, and
ER signiﬁcantly, compared with nondiabetic WT and
ECIRS1 TG mice at 3 and 7 days (Fig. 2A–E), although
no differences were observed between diabetic STZWT
and STZECIRS1 TG mice. VEGF mRNA expression in the
GT after 7 days of wound initiation was decreased by 38%
in STZ WT versus WT mice (P , 0.05) and in STZECIRS1
versus ECIRS1 mice (P , 0.01) (Supplementary Fig. 2D).
We also evaluated wound healing between STZWT mice
treated with insulin (STZWTins) and STZECIRS1 mice
treated with insulin (STZECIRS1ins). The results showed
that OWR was decreased (P , 0.05) and ER was incre-
ased (P , 0.01) in STZECIRS1ins mice compared with
STZWTins mice at 7 days after injecting (Supplementary
Fig. 3A–D).
Assessment of HF Diet–Induced Diabetes and
Hyperinsulinemia on Wound Healing
To determine whether diabetes and hyperinsulinemia
affect wound healing, we studied HF feeding in ECIRS1
TG (ECIRS1HF) and WT (WTHF) mice. After 10 weeks
of HF feeding, body weights were signiﬁcantly in-
creased in both WTHF and ECIRS1HF mice compared
with NC. Fasting blood glucose levels were elevated equal-
ly in both WTHF and ECIRS1HF mice to .200 mg/dL
(Supplementary Fig. 4A and B). IPGTTs were similarly
elevated; fasting and postinfusion glucose levels at
15 min .500 mg/dL (Supplementary Fig. 4C). Fasting
plasma insulin levels increased signiﬁcantly from 0.5 to
2.5 and 3.2 ng/dL in WTHF and ECIRS1HF mice (Sup-
plementary Fig. 4D). Fasting plasma IGF1 level also in-
creased in ECIRS1HF and WTHF mice (Supplementary
Fig. 4E). Interestingly, VEGF mRNA expressions were
increased in WTHF versus WT mice (P , 0.05) and in
Figure 4—Comparison of wound healing among WT, ECIRS1, WTHF, and ECIRS1HF mice. A: Photographs of wound at 0, 3, 7, 10, and
14 days after surgery. Black bar, 1 cm. B: OWR (%). C: CR (%). D: ER (%) (n = 5 for each type of mice and at each time point). *P < 0.05;
**P < 0.01.
diabetes.diabetesjournals.org Katagiri and Associates 2765
ECIRS1HF versus ECIRS1 TG mice by 276 and to 341%,
respectively (Fig. 3E). Analysis of the wound showed
HF feeding delayed OWR and ER at 3 and 7 days. Fur-
ther, ECIRS1HF mice had a signiﬁcantly greater re-
duction in OWR and increased ER than WTHF mice
at 3 and 7 days (Fig. 4A, B, and D). Thickness of GT
measured at 7 days after surgery was greater in
ECIRS1 TG versus WT mice (P , 0.01). HF feeding de-
creased GT thickness in both WTHF and ECIRS1HF
mice (P , 0.05) (Fig. 5A and B). Immunohistologi-
cal analysis of the GT showed the number of CD31+
cells, a marker for ECs and capillaries, was increased
in ECIRS1 TG versus WT mice (P , 0.01). HF feeding
for 10 weeks decreased CD31+ cells by 84% in WTHF
versus WT mice (Fig. 5C and D) and decreased by
63% in ECIRS1HF versus ECIRS1 TG mice. However,
a 290% elevation of CD31+ cell numbers was observed
in ECIRS1HF versus WTHF mice (P , 0.05) (Fig. 5C
and D).
Assessing HF Diet–Induced Insulin Resistance and
Diabetes on Angioblast and EC Distributions in GT
To characterize the potential mechanism for the reduction
of ECs in the GT associated with HF diet, the distribution
of angioblasts and ECs in the GT of WT and ECIRS1 TG
mice on NC and HF were characterized. Angioblasts were
identiﬁed by FLK1+, PI2, CD452, and CD312, and ECs
by CD452, PI2, and CD31+ cell staining. Angioblast num-
bers increased signiﬁcantly by 50% in ECIRS1 TG compared
with WT mice and by 65% in ECIRS1HF versus WTHF mice
(Fig. 6A and B). Interestingly, the elevations of angioblast
levels were similar between NC- and HF-fed WT and
ECIRS1 TG mice. EC numbers in GT increased by 95% in
ECIRS1 TG versus WT mice on NC. However, HF feeding
decreased EC levels by 72% in WTHF mice compared with
WT mice (P , 0.01). Similarly, ECIRS1 HF-fed mice also
had 64% less EC than ECIRS1 TG mice (Fig. 6A and B).
However, EC levels in the GT were signiﬁcantly increased
by 95% in ECIRS1 TG versus WT mice (Fig. 6B). IRS1
Figure 5—Histological analysis of the wound 7 days postsurgery in WT, ECIRS1, WTHF, and ECIRS1HF mice. A: Hematoxylin-eosin (HE)–
stained photograph. Black bar, 1 cm. B: Thickness of GT (n = 5). C: Immunohistochemistry (IHC) of GT. Blue, DAPI; green, CD31. D:
Percentage of CD31+ cells isolated from GT (n = 5). *P < 0.05; **P < 0.01. D, dermis; E, epidermis; F, fatty tissue; G, GT.
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overexpression in the EC only partially restored its reduc-
tion induced by HF feeding and diabetes with elevation of
ECs by 150% in ECIRS1 HF versus WTHF mice (Fig. 6B).
DNA synthesis of ECs and angioblasts was measured
by BrdU incorporation in GT and BM. Figure 7A showed
that proliferation of angioblasts in the GT was increased
by 47% in ECIRS1 TG versus WT mice (P , 0.05), but no
differences in BrdU incorporation were noted in these
cells in the BM (Fig. 7B). To determine whether the
elevation of angioblasts and ECs in the GT of ECIRS1
TG mice could also be due to uptake from circulation
rather than proliferation in situ, the uptake of circulat-
ing Lin2 and GFP+ cells, which were negative for PI,
B220, CD4, CD8, Ter119, CD11b, and Ly6G cells and
isolated from BM of GFP+ mice, were infused into WT
and ECIRS1 TG mice. Figure 7C and D showed that no
increases of GFP+ cells in the GT of ECIRS1 TG or WT
mice were observed.
Analysis of Insulin’s Signaling in Isolated Angioblasts
and ECs From GT
To support the ﬁndings that insulin actions could be
inhibited by HF diet and positively enhanced by IRS1
overexpression in ECs of ECIRS1 TG mice, IRS1 expressions
and signal changes in pAkt were studied in angioblasts and
ECs isolated from the GT. The results showed that IRS1
expression was increased speciﬁcally in the ECs of ECIRS1
TG mice by 291% (P , 0.01), but not in the angioblasts
(Fig. 8A and B). IRS1 expression was associated with the
expression of VE-cadherin since its promoter was used in
the transgene to make ECIRS1 TG mice (Supplementary
Fig. 1A). VE-cadherin expressions were only observed in
ECs but not in angioblasts (Fig. 8C). The levels of pAkt
stimulated by insulin (100 nmol/L) were similar in angio-
blasts from TG and WT mice (Fig. 8D) as assessed by FACS
using antibodies to pAkt. Similarly, HF feeding did not
affect pAkt levels in angioblasts from WT or ECIRS1TG
Figure 6—Characterization of angioblasts and ECs in GT by ﬂow cytometry at 7 days postsurgery in WT, ECIRS1, WTHF, and ECIRS1HF
mice. A: Angioblasts: PI2CD452Flk1+CD312; ECs: PI2CD452Flk12/+CD31+. B: Percentage of angioblasts and ECs in PI2CD452 cells.
*P < 0.05; **P < 0.01. n = 5.
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mice. Unlike angioblasts, insulin-induced pAkt levels in ECs
from GT were signiﬁcantly higher, by 196%, in ECIRS1TG
mice compared with WT mice (Fig. 8E). In contrast, insulin-
induced pAkt levels only increased by 127% in ECs isolated
from HF-fed ECIRS1HF compared with WTHF mice (Fig.
8E). Unlike the angioblasts, the levels of pAkt were signif-
icantly lower, by 50%, in the ECs of GT from ECIRS1 HF
mice versus from WT mice on NC (Fig. 8E). Similarly, pAkt
levels in the ECs from ECIRS1 HF were decreased by 64%
versus ECIRS1 TG mice. Nevertheless, insulin-induced pAkt
levels in ECs from ECIRS1 HF mice were still signiﬁcantly
higher than those fromWTHF mice, by 107% (Fig. 8E). The
levels of pAkt stimulated by VEGF (2.5 ng/mL) in angio-
blasts from GT were signiﬁcantly higher in WT mice com-
pared with WTHF mice (Fig. 8F).
DISCUSSION
This study demonstrated that enhancing insulin actions in the
ECs can improve wound healing in nondiabetic, diabetic, and
insulin-resistant states when insulin is present. Further, we
have identiﬁed a novel defect in the differentiation of
angioblast to EC with a parallel reduction of insulin-induced
pAkt as a potential mechanism for the deﬁciency in angio-
genesis in the GT induced by diabetes and insulin resistance.
Our study conﬁrmed that diabetes, whether due to
insulin deﬁciency or insulin resistance by HF diet, can
impair both angiogenesis and the wound healing process
(6,38,39). However, mechanisms causing the impaired
wound healing process may be different when diabetes
is due to insulin deﬁciency or obesity and insulin resistance.
In the insulin deﬁciency model, enhancement of insulin
Figure 7—Analysis of angioblast and EC proliferation and uptake in GT 7 days after surgery in WT and ECIRS1 TG mice. A: BrdU+ cells in
BM (n = 7). B: Percentage of angioblasts and ECs in PI2CD452 cells in BM. C: Flow cytometry analysis of uptake of lineage-negative cells in
GT (n = 6). D: GFP+ cells (%) in GT and blood 7 days after cell transplantation from GFP mice to WT and ECIRS1 TG mice. *P < 0.05.
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action in the ECs did not have any beneﬁcial effects on
wound healing, which supports the conclusion that the
improvement in ECIRS1 TG mice was likely due to the
enhancing of insulin’s actions in the ECs of the GTs. Eval-
uation of the GT in ECIRS1 TG mice showed a sequential
elevation of VEGF, FLK1, and VE-cadherin expressions af-
ter the initial injury compared with WT mice. These ﬁnd-
ings strongly supported the idea that improving insulin’s
actions in ECs enhanced VEGF expression and its signaling
cascades to improve angiogenesis and wound healing. It is
also possible that insulin may have perivascular effects due
to its speciﬁc action on the ECs, such as the activation
eNOS, to elevate NO and blood ﬂow from the increases
in angiogenesis to enrich the cells of the GT and improve
wound healing (20,33,34,40). Further, increased blood
ﬂow to GT has been reported to improve the inﬂux of inﬂam-
matory cells, which can enhance angiogenesis (21). Clearly,
the elevated VEGF expression in the GT observed in ECIRS1
TG mice is likely due to the enhancement of insulin signaling
through the IRS1/PI3K/Akt pathway, which has been shown
to regulate VEGF expression in ECs (14,40,41).
The reduced VEGF expression in the GT from STZ-
induced diabetic mice, which has been reported, is likely
due to insulin deﬁciency (3,6,42). This conclusion is sup-
ported by the ﬁndings of the paradoxical increases of
VEGF expression in GT from mice with HF-induced di-
abetes, which exhibited hyperinsulinemia rather than in-
sulin deﬁciency. Hyperinsulinemia may induce VEGF not
only in ECs but from ﬁbroblasts and inﬂammatory cells
(14,42). The paradoxical ﬁndings of VEGF expression in
GT indicate that the impaired angiogenesis in wound
healing may have different pathogenic mechanisms for
insulin-resistant and deﬁciency-induced diabetes. This
study provided the ﬁrst direct comparative analysis of
GT and wound healing between insulin-deﬁcient and
hyperinsulinemic and insulin-resistant models of diabe-
tes. A previous report showed that VEGF expression in
whole wound from HF-fed mice was similar to control
diet, but higher than ob/ob diabetic mice (39).
Interestingly, HF-induced obesity clearly caused defects
in GT formation and angiogenesis with decreased capillary
density, even in the presence of hyperinsulinemia, and
elevated VEGF levels, suggesting the possibility of re-
sistance to insulin or VEGF actions in the GT of WTHF
or ECIRS1HF mice. Analysis of GT cells indicated that
enhancing EC’s insulin action increased both angioblasts
Figure 8—Expression and insulin/VEGF activation of signaling molecules in angioblasts and ECs in GT from WT, ECIRS1, WTHF, and
ECIRS1HF mice. A: IRS1 mRNA expression in angioblasts. B: IRS1 mRNA expression in ECs of WT and ECIRS1 TG mice. C: VE-cadherin
mRNA expression in angioblasts and ECs. Analysis for insulin-induced (100 nmol/L) Akt phosphorylation in angioblasts (D) and ECs (E). F:
Analysis for VEGF-induced (2.5 ng/mL) Akt phosphorylation in angioblasts by using ﬂow cytometry measuring the mean of the peak of
ﬂuorescent intensity. *P < 0.05; **P < 0.01. n = 5. tAkt, total Akt.
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and ECs. Interestingly, diabetes and insulin resistance
inhibited only ECs and not angioblasts in the GT num-
bers. This provided the ﬁrst identiﬁcation that defect in
capillary formation in GT induced by diabetes or insulin
resistance is partly due to a selective inhibition in the
differentiation of angioblasts to ECs. Further, the reduc-
tion of ECs could only be partially normalized by improv-
ing insulin’s signaling in the ECs, even though VEGF
levels were elevated in HF conditions. Our results also
provide evidence that insulin can have actions on angio-
blasts, as shown by increasing DNA synthesis of angio-
blasts in the GT of ECIRS1 TG mice may not be inhibited
by obesity or diabetes since angioblast numbers were not
changed in these states. The effect of insulin to increase
angioblasts and ECs in the GT was the result of elevating
in situ cellular proliferation since there were no increases
in the uptake from infused GFP-labeled angioblasts or
ECs in WT or ECIRS1 TG mice. Signaling studies indicated
that HF diet–induced selective inhibition of insulin in-
duced pAkt in the ECs but not in the angioblasts, which
is consistent with the ﬁnding that HF diet did not de-
crease the number of angioblasts but only the ECs. These
ﬁndings conﬁrmed the idea that diabetes and insulin re-
sistance caused a selective defect in the differentiation of
angioblasts to ECs. By using the VE-cadherin promotor,
IRS1 overexpression is limited to ECs and not in angio-
blasts, which do not express VE-cadherin (43). This ap-
proach may not enhance angioblast differentiation to ECs,
which appears to be abnormal also in diabetes. This study
suggests that angioblasts are sensitive to insulin. Previ-
ously, Schatteman et al. (44) reported that circulating
angioblasts responded initially to insulin at 6–12 mg/mL,
but they become resistant after prolonged exposure,
which the authors suggested is the reason that the hyper-
insulinemia of type 2 diabetes could be causing poor angio-
genesis in wound healing. However, the level of insulin used
by Schatteman et al. (44), was 1 mmol/L, which is much
higher than physiological levels (,10 nmol/L), which makes
the ﬁnding difﬁcult to interpret for in vivo studies.
These studies provide documentation that diabetes
caused by insulin deﬁciency or diet-induced obesity
can induce a selective abnormality in the differentia-
tion of angioblasts to ECs in the GT, which is related to
resistance of pAkt activation induced by insulin and
possibly VEGF. Detailed studies to understand the mech-
anisms that are causing the inhibition of insulin or VEGF
activation of pAkt in the GT in diabetes will need to be
performed in the future. Further, we also observed that
enhancing insulin action speciﬁcally in the ECs through
the IRS1/PI3K/pAkt pathway could improve wound
healing both in nondiabetic and obesity-induced di-
abetes, suggesting a new therapeutic target for wound
healing.
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